Histocell join forces with seven companies in the Bio-Health area to launch the IMABI project

Print

Eight Basque companies, as well as various agents of the Basque Science, Technology and Innovation Network come together to research and develop new materials and biofunctional devices. The aim of this project is to promote intelligent specialisation and competitiveness of the Basque industrial fabric in the biomedical field.

The IMABI project is funded by the Department of Economic Development, Sustainability and Environment of the Basque Government through the SPRI Group within the Hazitek program and by the ERDF Funds of the European Union. This research is in development phase and is planned to conclude the following year. The purpose of the project is the research and subsequent development of biofunctional materials and the implementation of the processing technologies which are necessary for the integration of this biofunctionality in biomedical devices.

These improvements will allow, according to those responsible for IMABI, "an improvement in the health and quality of life of the patients who use them."

The IMABI project is integrated by companies. Developers and manufacturers of biofunctional materials for the regenerative medicine sector (Histocell, Polimerbio, I + Med), manufacturers of biomedical devices that need biofunctional capabilities in their products (AJL Ophthalmic, Osteophoenix and IMG Pharma) and Herrekor and Tecnalia Certificación industrial companies that carry out R & D in biofunctional materials. Likewise, this group is complemented by six agents of the Basque Science, Technology and Innovation Network (RVCTI) such as Tecnalia, UPV-EHU Gobe, Polymat, CIC nanoGUNE, Cidetec and Gaiker. These companies will be in charge of the research, development and innovation process of the products.

Histocell, for its part, is working on the formulation and testing of a product for the preventive treatment of Incontinence-Associated Dermatitis in adults (IAD). The new formulation will be designed to treat IAD-related partial thickness lesions by protecting both the epidermis and dermis layers and allowing the adequate healing. Furthermore, Histocell is focusing part of the work of this project on the study of the inhibitory effect of the products of its REOXCARE line on the generation and growth of biofilms, a growing problem in the field of wound healing.